Eckert & Ziegler SEXTER:EUZ -0.65%98 ROE % is 15.95% as of Mar. 2026, which is 8% above its 10-year median of 14.80. GuruFocus rates XTER:EUZ with a GF Score™ of 98/100 and a GF Value™ of €16.25 (Fairly Valued). Among 799 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 92.62% on this metric.
The historical rank and industry rank for Eckert & Ziegler SE's ROE % or its related term are showing as below:
XTER:EUZ'
s ROE % Range Over the Past 10 Years
Min: 9.32 Med: 14.8 Max: 20.76
Current: 20.48
During the past 13 years, Eckert & Ziegler SE's highest ROE % was 20.76%. The lowest was 9.32%. And the median was 14.80%.
XTER:EUZ's ROE % is ranked better than 92.62% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs XTER:EUZ: 20.48
Eckert & Ziegler SE (XTER:EUZ) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Eckert & Ziegler SE ROE % Related Terms
Eckert & Ziegler SE ROE % Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Eckert & Ziegler SE's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's ROE % distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Eckert & Ziegler SE (XTER:EUZ) has a ROE % of 15.95% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Eckert & Ziegler SE and its competitors. This is near median its historical median of 14.80. Over the past decade, Eckert & Ziegler SE's ROE % has ranged from 9.32 to 20.76. According to the industry distribution chart, Eckert & Ziegler SE ranks #59 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 7.4%.
Is Eckert & Ziegler SE's ROE % too high?
Eckert & Ziegler SE's current ROE % of 15.95% is near median its 10-year median of 14.80. Over the past 10 years, this metric has ranged from a low of 9.32 to a high of 20.76. The Medical Devices & Instruments industry median ROE % is 2.42. Eckert & Ziegler SE's value of 15.95% is 559.1% above this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #59 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #59 out of 799 companies for ROE %. This places Eckert & Ziegler SE in the top 7% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Eckert & Ziegler SE's value of 15.95% is 559.1% above this benchmark. Historically, Eckert & Ziegler SE's own ROE % has ranged from 9.32 to 20.76 over the past decade. While the company's 10-year median is 14.80 vs. the industry median of 2.42, Eckert & Ziegler SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current ROE % of 15.95% is 559.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current ROE % is 15.95%, which is near median its own 10-year median of 14.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (XTER:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.25, compared to a current price of €15.31 — trading 5.8% below its estimated fair value. The current ROE % is 15.95%, which is near median its 10-year median of 14.80 and 559.1% above the Medical Devices & Instruments industry median of 2.42. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Eckert & Ziegler SE (XTER:EUZ), the current ROE % is 15.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (XTER:EUZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.31 is trading 5.8% below its estimated GF Value™ of €16.25.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for XTER:EUZ:
ROE %: 15.95% (near median its 10-year median of 14.80)
GF Value™: €16.25 vs. price of €15.31 (5.8% below fair value)
Industry Position: 559.1% above the Medical Devices & Instruments median (#59 of 799)
No single metric tells the full story. See the XTER:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for XTER:EUZ
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:EUZ has been successfully added to your 
